Mexico - Delayed Quote • MXN Novartis AG (NVSN.MX) Follow 1,540.01 0.00 (0.00%) At close: April 12 at 12:19 PM CST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for NVSN.MX 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: NVSN.MX View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript Company News for Apr 24, 2024 Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria Why Novartis Stock Topped the Market on Tuesday FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock Novartis Stock Jumps After Beating Expectations, Raising Guidance Novartis Ag (NVS) Q1 2024 Earnings Call Transcript Novartis raises full-year guidance on Q1 beat, drug sales Incyte (INCY) to Report Q1 Earnings: What's in the Cards? Related Tickers BAYN.MU Bayer AG 27.40 +1.58% BAYN.SG Bayer AG 27.38 +1.80% GRF.MC Grifols, S.A. 8.39 +3.71% BAYN.DE Bayer Aktiengesellschaft 27.40 +1.88% BIIB Biogen Inc. 208.90 +3.18% LLY Eli Lilly and Company 733.51 +1.19% MRK Merck & Co., Inc. 131.20 +0.37%
